Neoplasma Vol.65, No.5, p.762-768, 2018
|
Title: Serum and urinary levels of CD222 in cancer: origin and diagnostic value |
Author: K. VICIKOVA, E. PETROVCIKOVA, P. MANKA, J. DRACH, H. STOCKINGER, V. LEKSA |
|
Abstract: The mannose 6-phosphate/insulin-like growth factor 2 receptor (CD222, M6P/IGF2R) is a multifunctional transmembrane type I receptor, mostly localized intracellularly and less on the surface of all types of mammalian cells. It is known to both transport lysosomal enzymes through their mannose 6-phosphate moieties and to internalize extracellular ligands such as insulin-like growth factor 2 or plasminogen. CD222 is involved in regulation of cell proliferation, migration, T cell activation and apoptosis, and soluble CD222 has been found in higher concentrations in the sera of liver disease patients. Herein, we analyzed the level of CD222 present in cancer patient serum and urine body fluids and found significantly elevated soluble CD222 levels in cancer patients’ sera compared to healthy controls, irrespective of disease type. The urinary CD222 levels were specifically increased in breast cancer and multiple myeloma. CD222 was present in CD222-positive exosomes in urine, but not in sera, thus identifying different CD222 origins present in human body fluids. These results inspire us to propose serum soluble CD222 as a general biomarker for tumorigenesis.
|
|
Keywords: mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R; CD222), cancer, exosomes, biomarker, serum, urine |
|
Published online: 24-Sep-2018
|
Year: 2018, Volume: 65, Issue: 5 |
Page From: 762, Page To: 768 |
doi:10.4149/neo_2018_171203N792
|
|
download file |
|
|
|
|